Imeglimin launch in Japan planned for 2021 after more good data

20 December 2019

Metabolic disease specialist Poxel (Euronext: POXEL) looked set to close Friday’s trading up more than 9%.

The French biotech company, along with its partner Sumitomo Dainippon Pharma (TYO: 4506), announced positive top-line results from TIMES 2, a Phase III trial evaluating imeglimin in combination with approved hypoglycemic therapies, and as a monotherapy, for the treatment of type 2 diabetes in Japan.

In line with the results from the TIMES 1 and TIMES 3 trials, the results from the TIMES 2 study, the third and final part of the program, have confirmed imeglimin’s efficacy and favorable safety profile as monotherapy and in combination with other existing therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK